Table 5.

Prospective trials comparing toxicity of amphotericin B in glucose or intralipid

Authors	Underlying disease (No of patients)	Infection treated	Preparation and administration of amphotericin B in intralipid
Chavanet et al12	HIV positive (22)	Oral candidiasis	1.0 mg/kg/day amphotericin B (mixed directly with intralipid 20%) as 1 hour intravenous infusion for 4 days*
Moreau et al13	Tumour (32)	Fever of unknown origin	0.7-1.0 mg/kg/day amphotericin B (dissolved in glucose then mixed with intralipid 20%) as a 4 hour intravenous infusion for 11/18 days*
Caillot et al14	Haematological disorders (42)	Fever or documented mycosis	1.0-1.1 mg/kg/day amphotericin B (mixed directly with intralipid 20%) as a 2 hour intravenous infusion for 8/12 days*
Thakur8	Kala-azar (22)	Visceral leishmaniasis	0.05-1.0 mg/kg/day amphotericin B (dissolved in water then mixed with intralipid 10%) as a 2-4 hour intravenous infusion until dose of 20 mg/kg reached*
Schoffski et al	Tumour (51)	Fever of unknown origin or pneumonia	0.75 mg/kg/day amphotericin B (Moreau type preparation) as a 1-4 hour intravenous infusion for 15/13 days**

^*Significant reduction of amphotericin B related side effects such as renal toxicity, fever, or chills.  

^**Significant increase in pulmonary toxicity without evidence of renal protection or improved subjective tolerance.